IRD (Opus Genetics) PB Ratio: (As of Jun. 25, 2026)


IRD Opus Genetics Inc IRD
24 GF Score
Price $3.67
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Opus Genetics's share price is $3.665. Opus Genetics's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.64. Hence, Opus Genetics's PB Ratio of today is .

The historical rank and industry rank for Opus Genetics's PB Ratio or its related term are showing as below:

During the past 7 years, Opus Genetics's highest PB Ratio was 25.65. The lowest was 0.75. And the median was 2.81.

IRD's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Opus Genetics's average Book Value Per Share Growth Rate was -673.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -53.70% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Opus Genetics was -43.50% per year. The lowest was -53.70% per year. And the median was -48.60% per year.

Back to Basics: PB Ratio


Opus Genetics  (NAS:IRD) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Opus Genetics PB Ratio Related Terms


Opus Genetics PB Ratio Historical Data

* Premium members only.

The historical data trend for Opus Genetics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics PB Ratio Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 3.16 1.59 1.45 5.59 9.14

Opus Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.77 3.23 17.93 9.14 0.00

IRD vs IFRX, RGNX, LRMR: PB Ratio Comparison

For the Biotechnology subindustry, Opus Genetics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Opus Genetics's PB Ratio falls into.


IRD
24GF Score
Opus Genetics Inc IRD
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Opus Genetics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=3.665/-0.642
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $3.67 is trading 890.5% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • PB Ratio:
  • GF Value™: $0.37 vs. price of $3.67 (890.5% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.67
Price
$0.37
GF Value